Want to see GALT full AI Analyst Report?
GALT Stock Chart & Stats
$5.71
-$0.06(-5.00%)
At close: 4:00 PM EST
$5.71
-$0.06(-5.00%)
Day’s Range― - ―
52-Week Range$2.03 - $7.13
Previous CloseN/A
Volume135.57K
Average Volume (3M)832.83K
Market Cap
$287.79M
Enterprise Value$304.03M
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$135.72M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 17, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding65,856,895
10 Day Avg. Volume1,252,433
30 Day Avg. Volume832,832
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-16.33
Forecast
1Y Price Target
$11.00Price Target Upside92.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Clarity: FDA Phase 3 AlignmentFormal FDA agreement on endpoints, trial design and a traditional full‑approval pathway materially reduces regulatory execution risk. That durable clarity increases the program's credibility with partners and investors, strengthens ability to design a single confirmatory trial, and aids long-term planning and fundraising discussions.
Mechanism-focused Pipeline Targeting Galectin-3A clear biological target (galectin‑3) linked to fibrosis and inflammation provides a durable scientific rationale across multiple indications. This differentiated mechanism supports potential label expansion, partner interest, and strategic licensing opportunities that can convert clinical success into multiple commercial pathways over time.
Improving Cash Burn TrendsProgressive reduction in cash burn indicates management has tightened spending and improved operating efficiency, extending runway versus prior years. While still cash‑consuming, the trend lessens immediate financing pressure, improving the company's ability to execute near‑term clinical milestones and negotiate partnerships without acute liquidity stress.
Bears Say
No Revenue BaseA complete absence of operating revenue means the company cannot internally fund development or offset R&D expense, creating chronic reliance on external capital. Over the medium term this elevates dilution risk, constrains strategic options, and requires successful clinical or partnership milestones to materially alter the funding profile.
Highly Leveraged, Negative Equity Balance SheetDeeply negative equity paired with substantial debt and minimal assets limits financial flexibility and increases refinancing and covenant risk. Over months this structure can constrain partner negotiations, raise borrowing costs, and heighten insolvency risk if clinical or funding events fail to materialize, making long‑term execution fragile.
Dependence On Financing And PartnersThe firm's business model depends on periodic capital raises and partner transactions rather than operating cash flow. This structural dependency raises the probability of dilution, deal timing risk, and execution risk: successful continuation of programs hinges on securing external financing or collaborators under acceptable terms.
Galectin Therapeutics News
GALT FAQ
What was Galectin Therapeutics (GALT)’s price range in the past 12 months?
Galectin Therapeutics (GALT) lowest stock price was $2.02 and its highest was $7.13 in the past 12 months.
What is Galectin Therapeutics (GALT)’s market cap?
Galectin Therapeutics (GALT)’s market cap is $287.79M.
When is Galectin Therapeutics (GALT)’s upcoming earnings report date?
Galectin Therapeutics (GALT)’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were Galectin Therapeutics (GALT)’s earnings last quarter?
Galectin Therapeutics (GALT) released its earnings results on May 15, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.08.
Is Galectin Therapeutics (GALT) overvalued?
According to Wall Street analysts Galectin Therapeutics (GALT)’s price is currently Undervalued.
Does Galectin Therapeutics (GALT) pay dividends?
Galectin Therapeutics (GALT) does not currently pay dividends.
What is Galectin Therapeutics (GALT)’s EPS estimate?
Galectin Therapeutics (GALT)’s EPS estimate is -0.09.
How many shares outstanding does Galectin Therapeutics (GALT) have?
Galectin Therapeutics (GALT) has 65,856,895 shares outstanding.
What happened to Galectin Therapeutics (GALT)’s price movement after its last earnings report?
Galectin Therapeutics (GALT) reported an EPS of -$0.08 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.66%.
Which hedge fund is a major shareholder of Galectin Therapeutics (GALT)?
Currently, no hedge funds are holding shares in GALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (92.64% Upside)
$11.00 (92.64% Upside)
Blogger Sentiment
Bullish
GALT Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.71%
12-Months-Change
Fundamentals
Return on Equity
21.05%
Trailing 12-Months
Asset Growth
65.40%
Trailing 12-Months
Company Description
Galectin Therapeutics (GALT)
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
GALT Stock 12 Month Forecast
Average Price Target
$11.00
▲(92.64% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
26.04% Insiders
3.90% Mutual Funds
0.02% Other Institutional Investors
64.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---